Esophageal Malignancy
Conditions
Interventions
Experimental Group (Morphine Group):Following standard anesthesia induction and maintenance, patients in the experimental group received 6 mL of 0.125% ropivacaine combined with 2 mg morphine hydrochl
Control Group (non-Morphine Group):Following standard anesthesia induction and maintenance, patients in the control group received 6 mL of 0.125% ropivacaine (without morphine) via the indwelling epid
Sponsors
Nanjing Drum Tower Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Patients who are scheduled to undergo mediastoscopic resection of oesophageal cancer; (2) Age >=65 years old and <80 years old; (3) BMI 18-30 kg/m^2; (4) Those who voluntarily participate and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Physical functional disorders (including language, hearing and visual impairments) existed before admission; (2) Severe diseases of the heart, lungs, liver and kidneys; (3) Patients with severe hypertension, glaucoma or elevated intracranial pressure, as well as those with untreated or undertreated hyperthyroidism; (4) Patients with severe neuropsychiatric disorders (hysteria, dementia) or cognitive impairments; (5) Long-term use of analgesic and sedative drugs, anticoagulants or alcohol abuse, and allergy to anesthesia-related drugs; (6) Conversion to thoracotomy; (7) Coagulation dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative acute pain intensity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative Early Pulmonary Complications;Postoperative Tracheal Extubation Time;Intraoperative and Postoperative Adverse Events and Management;Cancer recurrence rate; | — |
Countries
China
Contacts
Public ContactQun Fu, Leiyuan Wang
Nanjing Drum Tower Hospital
Outcome results
None listed